Literature DB >> 3140967

Patients as a direct source of information on adverse drug reactions.

A S Mitchell1, D A Henry, R Sanson-Fisher, D L O'Connell.   

Abstract

To determine whether patients should participate directly in detecting adverse reactions to drugs their ability to provide written reports of symptoms experienced during treatment with amoxycillin or trimethoprim-sulphamethoxazole was investigated. When compared with telephone interviews forms on which patients reported events were reliable (the observed agreement with the same statements posed during telephone calls was 85%, kappa = 0.56) and valid (sensitivity = 54%, specificity = 94%). Patients were also supplied with forms that invited them to report adverse reactions, and their perceptions were compared with those of a panel of experts, who were informed of all clinical events that had been reported during the detailed telephone interviews. Patients were more conservative than the experts in attributing clinical events to drug treatment. The extent of agreement varied and was notably poor for skin and bowel complaints (kappa = 0.13 in each case). The performance of event report forms and reaction report forms as instruments of detection was compared in a hypothetical situation in which the experts' views represented the "truth" about adverse reactions to a new drug. Event reporting had a higher sensitivity than reaction reporting (42% v 24%) but a lower specificity (58% v 98%). National centres monitoring adverse drug reactions should probably resist pressure to accept reports of reactions directly from the public, but a system based on large scale reporting of events might be valuable in aiding the early detection of symptomatic reactions to new drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140967      PMCID: PMC1834468          DOI: 10.1136/bmj.297.6653.891

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  Clinical biostatistics XXXI. On the sensitivity, specificity, and discrimination of diagnostic tests.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

2.  Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.

Authors:  D G Colin-Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-19

3.  The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance.

Authors:  B L Strom; J L Carson; M L Morse; A A LeRoy
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

4.  Postmarketing follow-up at Group Health Cooperative of Puget Sound.

Authors:  H Jick; S Madsen; P M Nudelman; D R Perera; A Stergachis
Journal:  Pharmacotherapy       Date:  1984 Mar-Apr       Impact factor: 4.705

5.  Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton.

Authors:  W H Inman
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-11

6.  A methodologic study of post-marketing drug evaluation using a pharmacy-based approach.

Authors:  E K Borden; J G Lee
Journal:  J Chronic Dis       Date:  1982

7.  Patient-initiated postmarketing surveillance: a validation study.

Authors:  S Fisher; S G Bryant; B L Solovitz; R M Kluge
Journal:  J Clin Pharmacol       Date:  1987-11       Impact factor: 3.126

8.  Postmarketing drug surveillance by record linkage in Tayside.

Authors:  I K Crombie; S V Brown; J G Hamley
Journal:  J Epidemiol Community Health       Date:  1984-09       Impact factor: 3.710

  8 in total
  25 in total

Review 1.  Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Authors:  W K Kraft; S A Waldman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world.

Authors:  Rohini B M Fernandopulle; Krisantha Weerasuriya
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 3.  Over-the-counter self-medication. The issues.

Authors:  A Mant; S Whicker; Y S Kwok
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

4.  Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Authors:  M C Reilly; A S Zbrozek
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

5.  Adverse event reporting for herbal medicines: a result of market forces.

Authors:  Rishma Walji; Heather Boon; Joanne Barnes; Zubin Austin; G Ross Baker; Sandy Welsh
Journal:  Healthc Policy       Date:  2009-05

Review 6.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

Authors:  A Blenkinsopp; P Wilkie; M Wang; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

7.  Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

Authors:  Lise Aagaard; Lars Hougaard Nielsen; Ebba Holme Hansen
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Adverse drug reactions.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  1991-11

9.  Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals.

Authors:  T C Egberts; M Smulders; F H de Koning; R H Meyboom; H G Leufkens
Journal:  BMJ       Date:  1996-08-31

10.  Regional surveillance of emergency-department visits for outpatient adverse drug events.

Authors:  A Capuano; A Irpino; M Gallo; L Ferrante; M L Illiano; B Rinaldi; A Filippelli; F Rossi
Journal:  Eur J Clin Pharmacol       Date:  2009-03-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.